{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:10:30Z","timestamp":1761887430222,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.nrleng.2022.04.004","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T16:05:10Z","timestamp":1683648310000},"page":"309-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute inflammatory demyelinating polyneuropathy shortly after administration of intravitreal ranibizumab"],"prefix":"10.1016","volume":"38","author":[{"given":"A.","family":"Fuerte-Hortig\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garc\u00eda-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"S\u00e1nchez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2022.04.004_bib0080","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","article-title":"Ranibizumab","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0085","unstructured":"Lucentis (ranibizumab) FDA approval history \u2013 Drugs.com. (n.d.). Retrieved February 2021 from https:\/\/www.drugs.com\/history\/lucentis.html"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0090","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology. 2013 Jan;120(1):209\u201310]","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0095","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40264-017-0553-y","article-title":"Overview of the safety of anti-VEGF drugs: analysis of the italian spontaneous reporting system","volume":"40","author":"Cutroneo","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.nefro.2016.10.011","article-title":"Renal damage associated to intravitreal administration of ranibizumab. Da\u00f1o renal asociado a la administraci\u00f3n intrav\u00edtrea de ranibizumab","volume":"37","author":"Morales","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0120","first-page":"592","article-title":"Guillain-Barr\u00e9 syndrome following adalimumab treatment","volume":"30","author":"Manganelli","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1152\/physrev.00031.2008","article-title":"Role and therapeutic potential of VEGF in the nervous system","volume":"89","author":"Ruiz de Almodovar","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0130","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1096\/fj.12-225185","article-title":"Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea","volume":"27","author":"Pan","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0135","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJM199204233261706","article-title":"The Guillain-Barr\u00e9 syndrome","volume":"326","author":"Ropper","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/157016111796642670","article-title":"Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration","volume":"9","author":"Semeraro","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annepidem.2013.12.009","article-title":"Peripheral neuropathy and Guillain-Barr\u00e9 syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis","volume":"24","author":"Ali","year":"2014","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.nrleng.2022.04.004_bib0150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/WNL.0000000000000846","article-title":"Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study","volume":"83","author":"Etminan","year":"2014","journal-title":"Neurology"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082200150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S217358082200150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:34:35Z","timestamp":1761881675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S217358082200150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S217358082200150X"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2022.04.004","relation":{},"ISSN":["2173-5808"],"issn-type":[{"type":"print","value":"2173-5808"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute inflammatory demyelinating polyneuropathy shortly after administration of intravitreal ranibizumab","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2022.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}